APR 24, 2020 1:10 AM PDT

Combination Immunotherapy Allows Immune Cells To Target Tumors

WRITTEN BY: Nouran Amin

A drug combination of immunotherapeutic agents encourages immune cells to devour cancer cells according to findings published in Nature Communications.

By blocking the CD47 protein—a marker on cancer cells that prevents them from being tracked by immune cells—tumors can be vulnerable to immune surveillance.

Learn more about cancer and the immune system:

“In recent years, researchers have had considerable success in harnessing the immune system to fight some cancers, developing several drugs that have vastly extended survival,” explains study leader Wen Jiang, M.D., Ph.D., assistant professor of radiation oncology at UT Southwestern Medical Center.

Researchers began the inhibition process by administering the temozolomide (TMZ) therapeutic—a drug that promotes stress responses in cancer cells making the immune system more likely to ‘capture’ them.

“Although this drug also increased phagocyte consumption of the cancer cells, these results were also lackluster,”says Jiang, also a member of UT Southwestern's Harold C. Simmons Comprehensive Cancer Center.

"If a new therapy extends survival by even one to two months, it's considered a blockbuster drug," Jiang says. "Here, we're talking potentially about a significant proportion of patients who could be cured. Bridging the innate and adaptive immune systems could prove to be a major advance for GBM."

Source: Science Daily

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
APR 04, 2020
Cancer
APR 04, 2020
Unique Cancer Mutation Hijacks Nearby Signaling Pathway
  In cancer, tyrosine kinase mutations are quite common. MET is one such example that normally binds its native lig ...
APR 01, 2020
Cancer
APR 01, 2020
New immunotherapy for ovarian cancer
Research published recently in the Journal of Experimental Medicine suggests that targeting macrophages in a new kind of ...
APR 08, 2020
Drug Discovery & Development
APR 08, 2020
Does Tuberculosis Vaccine Really Defend from COVID-19?
The spread of COVID-19 has panned out very differently in different countries. While in some such as the US, the UK and ...
APR 10, 2020
Drug Discovery & Development
APR 10, 2020
Cardiac Patch Repairs Heart Attack Damage in Pigs and Rats
Heart attacks significantly damage cardiac tissue. Recovery time frames from a heart attack thus depend on the extent to ...
APR 22, 2020
Drug Discovery & Development
APR 22, 2020
Only 3% of COVID-19 Antibody Tests Approved by FDA
So far, only 3% of at least 90 COVID-19 antibody tests in the US have been approved by the Food and Drug Administration ...
APR 30, 2020
Drug Discovery & Development
APR 30, 2020
Shortcuts in Drug Development may Cause Long Term Damage
   
Loading Comments...